A Phase I, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess Safety,Tolerability, Pharmacokinetics and Efficacy of MEDI-578, an Anti-NGF Monoclonal Antibody, After Single Ascending Doses in Male and Non-fertile Female Patients With Painful Osteoarthritis of the Knee.
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2013
At a glance
- Drugs MEDI 578 (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Adverse reactions
- 26 Nov 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 26 Nov 2010 Planned end date changed from 1 Oct 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 13 Jul 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.